Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology
Diagnostics · 21.01.2026 · 16 (2) · 341
DOI: 10.3390/diagnostics16020341 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diagnostics, online erschienen am 21.01.2026. Verfasst von Federico Sabuzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine and Prevention, University Hospital of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Recurrent brain tumors—including high-grade gliomas, brain metastases, and aggressive meningiomas—continue to carry a poor prognosis, with high mortality despite therapeutic advances. The aim of this narrative review is to summarize and critically discuss the current evidence on the role of intra-arterial radioligand therapy (RLT) in the treatment of recurrent brain tumors. RLT, a targeted form of radionuclide therapy, has gained increasing attention for its potential theranostic applications in neuro-oncology. A literature search was conducted using PubMed and Scopus, including clinical studies evaluating intra-arterial radioligand delivery in central nervous system tumors. Recent research has explored intra-arterial administration of radioligands targeting somatostatin receptors and prostate-specific membrane antigen (PSMA). Somatostatin receptors are overexpressed in meningiomas, while PSMA is highly expressed in the neovasculature of glioblastomas and brain metastases; both targets can be addressed using lutetium-177 (177Lu)- or actinium-225 (225Ac)-labeled radiopharmaceuticals, traditionally delivered intravenously. Available evidence indicates that the intra-arterial route achieves markedly higher radionuclide uptake on 68Ga-PSMA-11 and 68Ga-DOTATOC PET, as well as increased absorbed doses in dosimetric models. Dosimetric analyses consistently show greater tracer accumulation compared with intravenous administration, without evidence of significant peri-procedural toxicity. Uptake in healthy brain tissue is minimal, and no relevant differences have been reported in liver or salivary gland accumulation between intra-arterial and intravenous RLT. Although based on heterogeneous and limited data, intra-arterial RLT appears to be a promising therapeutic strategy for recurrent brain tumors. Future research should focus on improving radioligand delivery beyond the blood–brain barrier and enhancing effective tumor targeting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedicine and Prevention, University Hospital of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.
- Department of Chemical Science and Technologies, University of Rome "Tor Vergata", Via della Ricerca Scientifica 1, 00133 Rome, Italy.
ORCID-Profile: Federico Sabuzi, Luca Filippi, Mariafrancesca Trulli, Fabio Domenici, Valerio Da Ros
Zitieren
APA
Sabuzi, F., Filippi, L., Trulli, M., Domenici, F., Garaci, F., & Da Ros, V. (2026). Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology. Diagnostics, 16(2), 341. https://doi.org/10.3390/diagnostics16020341
Vancouver
Sabuzi F, Filippi L, Trulli M, Domenici F, Garaci F, Da Ros V. Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology. Diagnostics. 2026;16(2):341. doi:10.3390/diagnostics16020341
BibTeX
@article{Sabuzi2026,
author = {Sabuzi, Federico and Filippi, Luca and Trulli, Mariafrancesca and Domenici, Fabio and Garaci, Francesco and Da Ros, Valerio},
title = {Intra-Arterial Radioligand Therapy in Brain Cancer: Bridging Nuclear Medicine and Interventional Neuroradiology},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {2},
pages = {341},
doi = {10.3390/diagnostics16020341}
}
EUVIMED